Krystel Feghali, MD
Endocrinology, Diabetes & Metabolism · Springfield, MANPI 1982055141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.
Across 176 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$655
- AbbVie$586
- Abbott$548
- Novo Nordisk$191
- Lilly USA, LLC$169
- Boehringer Ingelheim$155
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,46399%
- Education$201%
- Other$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $655 |
| AbbVie | 28 | $586 |
| Abbott | 42 | $548 |
| Novo Nordisk | 9 | $191 |
| Lilly USA, LLC | 7 | $169 |
| Boehringer Ingelheim | 7 | $155 |
| Johnson & Johnson(2 entities) | 7 | $140 |
| Pfizer | 1 | $121 |
| Medtronic | 4 | $100 |
| Xeris Pharmaceuticals, Inc. | 5 | $95 |
| Ascendis Pharma Endocrinology Inc | 4 | $88 |
| AstraZeneca | 4 | $84 |
| Tandem Diabetes Care, Inc. | 3 | $71 |
| Corcept Therapeutics | 4 | $65 |
| IBSA Pharma Inc. | 3 | $63 |
| Bayer | 3 | $55 |
| Dexcom, Inc. | 2 | $51 |
| Mannkind Corporation | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Radius Health, Inc. | 2 | $42 |
| BETA Bionics, Inc. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Cequr Corporation | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Insulet Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$121
How this compares
$3,502 in reported general payments places this provider in the 70th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 262 | $407,853 |
| TrulicityDulaglutide | 253 | $363,944 |
| OzempicSemaglutide | 152 | $268,389 |
| JardianceEmpagliflozin | 232 | $265,558 |
| RybelsusSemaglutide | 46 | $93,520 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 61 | $87,524 |
| ProliaDenosumab | 27 | $46,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 189 | $33,253 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $30,748 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $29,053 |
| FarxigaDapagliflozin Propanediol | 18 | $19,659 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $14,584 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $14,377 |
| Humalog Kwikpen U-100Insulin Lispro | 29 | $13,946 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $12,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $169 | $771,798515 claims |
| Novo NordiskOzempic, Rybelsus | $191 | $361,908198 claims |
| Boehringer IngelheimJardiance | $155 | $265,558232 claims |
| AmgenProlia, Evenity (2 Syringes) | $655 | $75,97739 claims |
| AstraZenecaFarxiga | $84 | $19,65918 claims |
| Sanofi-aventis U.S. LLCAdmelog | $44 | $7,54712 claims |
| IBSA Pharma Inc.Tirosint | $63 | $4,21827 claims |
| AbbVieSynthroid | $586 | $3,30825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Springfield
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.